Analysis
QuantHealth raised a $45 million Series B led by Qumra Capital, according to the [Tech Startups funding roundup](https://techstartups.com/2026/08/04/venture-capital-startup-funding-roundup-august-4-2026-a16z-base10-dream-ventures-jpmorgan-sequoia-capital-valor-equity-partners-yc-more/) for August 4. The company, which operates out of New York and Tel Aviv, sells AI-driven clinical trial simulation to pharmaceutical developers.
The pitch targets the most expensive failure in drug development: a Phase II or Phase III trial that reads out negative because the protocol was designed wrong -- wrong endpoint, wrong dose, wrong patient population -- rather than because the molecule does not work. Those failures cost hundreds of millions of dollars and years of patent life. Simulating candidate protocols against modeled patient populations before enrollment is an attempt to move that decision earlier and make it cheaper.
“The last of those is the real competitor: a $45 million Series B has to win against a customer's own team, which has more proprietary trial data than any vendor.”
QuantHealth sits in a field that now includes Unlearn.AI on digital twins, Medidata's simulation tools inside Dassault, and internal data science groups at every large pharma company. The last of those is the real competitor: a $45 million Series B has to win against a customer's own team, which has more proprietary trial data than any vendor.
The number that decides this business is not ARR -- it is whether any sponsor will point to a specific trial whose design changed on the strength of a simulation and whose readout was positive. Pharma buys on evidence, and the sales cycle runs years. Watch for a named sponsor case study and a publication in a peer-reviewed journal; without one, this stays a pilot business regardless of how much capital is behind it.
